EP1187633A4 - Utilisation d'anticorps anti-vegf pour accentuer le rayonnement lors d'une therapie anticancereuse - Google Patents

Utilisation d'anticorps anti-vegf pour accentuer le rayonnement lors d'une therapie anticancereuse

Info

Publication number
EP1187633A4
EP1187633A4 EP00931923A EP00931923A EP1187633A4 EP 1187633 A4 EP1187633 A4 EP 1187633A4 EP 00931923 A EP00931923 A EP 00931923A EP 00931923 A EP00931923 A EP 00931923A EP 1187633 A4 EP1187633 A4 EP 1187633A4
Authority
EP
European Patent Office
Prior art keywords
cancer therapy
vegf antibody
enhance radiation
enhance
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00931923A
Other languages
German (de)
English (en)
Other versions
EP1187633A1 (fr
Inventor
Ralph R Weichselbaum
Donald W Kufe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Arch Development Corp filed Critical Dana Farber Cancer Institute Inc
Publication of EP1187633A1 publication Critical patent/EP1187633A1/fr
Publication of EP1187633A4 publication Critical patent/EP1187633A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
EP00931923A 1999-04-08 2000-04-07 Utilisation d'anticorps anti-vegf pour accentuer le rayonnement lors d'une therapie anticancereuse Withdrawn EP1187633A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12871399P 1999-04-08 1999-04-08
US128713P 1999-04-08
PCT/US2000/009255 WO2000061186A1 (fr) 1999-04-08 2000-04-07 Utilisation d'anticorps anti-vegf pour accentuer le rayonnement lors d'une therapie anticancereuse

Publications (2)

Publication Number Publication Date
EP1187633A1 EP1187633A1 (fr) 2002-03-20
EP1187633A4 true EP1187633A4 (fr) 2005-05-11

Family

ID=22436614

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00931923A Withdrawn EP1187633A4 (fr) 1999-04-08 2000-04-07 Utilisation d'anticorps anti-vegf pour accentuer le rayonnement lors d'une therapie anticancereuse

Country Status (3)

Country Link
EP (1) EP1187633A4 (fr)
AU (1) AU4972900A (fr)
WO (1) WO2000061186A1 (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US7273751B2 (en) 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
ATE470676T1 (de) 2001-04-13 2010-06-15 Human Genome Sciences Inc Anti-vegf-2 antikörper
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CA2494061C (fr) 2002-07-31 2011-06-14 Wayne R. Danter Inhibiteurs de proteine tyrosine kinase
ATE380810T1 (de) 2002-10-09 2007-12-15 Critical Outcome Technologies Protein-tyrosine-kinase-inhibitoren
DK1761515T3 (da) 2003-12-20 2009-02-16 Merck Patent Gmbh 2-(hetero-)aryl-substituerede tetrahydroquinolinderivater
WO2006123182A2 (fr) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Sulfones de cyclohexyle pour le traitement du cancer
DE102005061840A1 (de) 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20070264193A1 (en) * 2006-03-29 2007-11-15 Genentech, Inc. Diagnostics and treatments for tumors
WO2008039327A2 (fr) 2006-09-22 2008-04-03 Merck & Co., Inc. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
DE102007013855A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
DE102007013854A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Tetrahydrochinoline
DE102007013856A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydropyrrolochinoline
BRPI0812159A2 (pt) 2007-05-21 2017-05-02 Novartis Ag inibidores de csf-1r, composições e métodos de uso
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
DE102007047735A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
DE102007047738A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
DE102007047737A1 (de) 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
DE102007049451A1 (de) 2007-10-16 2009-04-23 Merck Patent Gmbh 5-Cyano-thienopyridine
EP2222636B1 (fr) 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Modulateurs sélectifs du récepteur androgène (sarm) et leurs utilisations
WO2009079797A1 (fr) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Composés et procédé pour le traitement du cancer
DE102008017853A1 (de) 2008-04-09 2009-10-15 Merck Patent Gmbh Thienopyrimidine
WO2009129335A2 (fr) 2008-04-15 2009-10-22 Pharmacyclics, Inc. Inhibiteurs sélectifs de l'histone désacétylase
EP3023426A1 (fr) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Composés inhibiteurs à base de thiosemicarbazone et procédés de traitement du cancer
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
EP2413932A4 (fr) 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibiteurs de l'activité akt
JP5767205B2 (ja) 2009-04-02 2015-08-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ オートタキシン阻害剤としての複素環式化合物
AU2010230585B2 (en) 2009-04-02 2016-03-24 Merck Patent Gmbh Autotaxin inhibitors
MX2011010203A (es) 2009-04-02 2011-10-14 Merck Patent Gmbh Derivados de piperidina y piperazina como inhibidores de autotaxina.
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
DE102009033392A1 (de) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
DE102009049211A1 (de) 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
EA201200653A1 (ru) 2009-11-07 2013-01-30 Мерк Патент Гмбх Гетариламинохинолины
CA2784807C (fr) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
EP2531500B1 (fr) 2010-02-05 2018-01-24 Merck Patent GmbH Dérivés d'hétaryl-[1,8]naphtyridine
BR112012019561A2 (pt) 2010-02-22 2019-09-24 Merck Patent Gmbh hetarilamino naftiridinas
CA2793299A1 (fr) 2010-03-16 2011-09-22 Merck Patent Gmbh Morpholinylchinazoline
BR112012023021A2 (pt) 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc compostos de indazol e seus usos
JP5827677B2 (ja) 2010-03-26 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ オートタキシン阻害剤としてのベンゾナフチリジンアミン
CA2794952C (fr) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Composes et methodes pour le traitement du vih
EP2584903B1 (fr) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
EP2585461B1 (fr) 2010-06-28 2020-02-26 Merck Patent GmbH [1,8]naphthyridines 2,4-diaryl-substitués en tant qu'inhibiteurs de kinases pour le traitement des cancers
DE102010025786A1 (de) 2010-07-01 2012-01-05 Merck Patent Gmbh Pyrazolochinoline
CA2804285C (fr) 2010-07-05 2019-05-14 Merck Patent Gmbh Derives de bipyridyl utiles pour le traitement de maladies induites par des kinases
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
EP2608669B1 (fr) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
EP2613782B1 (fr) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
CA2809892C (fr) 2010-09-02 2019-05-28 Merck Patent Gmbh Derives de pyrazolopyridinone en tant qu'antagonistes de recepteur de lpa
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012087772A1 (fr) 2010-12-21 2012-06-28 Schering Corporation Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
BR112013022948A2 (pt) 2011-03-09 2016-12-06 Merck Patent Gmbh derivados de pirido [2,3 - b] pirazina e seus usos terapêuticos
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
CN103717609B (zh) 2011-05-31 2016-05-11 江苏康缘药业股份有限公司 聚(adp-核糖)聚合酶的三环抑制剂
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
WO2013074986A1 (fr) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase c-jun-n-terminale (jnk)
DE102011118830A1 (de) 2011-11-18 2013-05-23 Merck Patent Gmbh Morpholinylbenzotriazine
EP3919620A1 (fr) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063054A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
EP2951180B1 (fr) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2015058126A1 (fr) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Composés hétéroaromatiques utiles dans le traitement de maladies prolifératives
WO2015164614A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase et leurs utilisations
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016160617A2 (fr) 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
EP3307728A4 (fr) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
EP3347018B1 (fr) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
EP3475275B1 (fr) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 5-trifluorométhyl-oxadiazoles substitués en 3-aryle et hétéroaryle en tant qu'inhibiteurs de l'histone désacétylase 6 (hdac6)
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2019148412A1 (fr) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anticorps bispécifiques anti-pd-1/lag3
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
US20230108452A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GORSKI D H ET AL: "Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, 15 July 1999 (1999-07-15), pages 3374 - 3378, XP002256383, ISSN: 0008-5472 *
LEE C G ET AL: "The effect of combined anti-VEGF mAb and radiation vs. radiation alone or anti-VEGF mAb alone on human tumor xenografts", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03-01), & 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999, pages 200, XP001204640, ISSN: 0197-016X *
See also references of WO0061186A1 *

Also Published As

Publication number Publication date
WO2000061186A1 (fr) 2000-10-19
EP1187633A1 (fr) 2002-03-20
AU4972900A (en) 2000-11-14

Similar Documents

Publication Publication Date Title
EP1187633A4 (fr) Utilisation d'anticorps anti-vegf pour accentuer le rayonnement lors d'une therapie anticancereuse
HK1038512A1 (en) Methods of inducing cancer cell death and tumor regression
HUS1500001I1 (hu) ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
EP0926955A4 (fr) Conjugues utiles dans le traitement du cancer de la prostate
PL368458A1 (en) Improved use of antitumoral compound in cancer therapy
HUP0000651A3 (en) Conjugates useful in the treatment of prostate cancer
AU6098600A (en) Determining antibodies to ny-eso-1 in cancer patients
EP1320376A4 (fr) Traitement du cancer de la prostate
IL147748A0 (en) Use of etodolac to treat cancer
EP1373221A4 (fr) Nouveaux composes de dihydropyrimidine cyano substituee et leur utilisation therateutique
EP1539197A4 (fr) Traitement de cellules tumorales destinees a l'immunotherapie du cancer
IL156690A0 (en) Specific human antibodies for selective cancer therapy
AU2002351374A8 (en) Antibodies to treat cancer
PL371202A1 (en) Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
EG22346A (en) Process for the preparation of conjugates useful in the treatment of prostate cancer
EP1427754A4 (fr) Acide nucleique et polypeptide lies au cancer du sein et leurs utilisations
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
EP1225919A4 (fr) Traitement du cancer
AU1576501A (en) Methods to enhance and confine gene expression in cancer therapy
EP1349555A4 (fr) Traitement du cancer par reduction d'energie intracellulaire et a l'aide de pyrimidines
GB0022216D0 (en) Human FAP-a-specific antibodies for use in cancer therapy
SI1229936T1 (en) Use of anti-idiotypical antibodies as vaccines against cancer
GB9907538D0 (en) Materials and methods relating to treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011008

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050401

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE UNIVERSITY OF CHICAGO

Owner name: DANA-FARBER CANCER INSTITUTE, INC.

17Q First examination report despatched

Effective date: 20060512

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090514